RenovoRx (RNXT) CEO Issues Update Letter

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. CSX
7. LRCX
8. MRK
9. LVS
10. SAP

Go back to RenovoRx (RNXT) CEO Issues Update Letter

RenovoRx CEO Issues Update Letter to Shareholders

May 30, 2024 8:30 AM EDT

With $17.2 million in gross proceeds raised since the beginning of 2024, RenovoRx is well positioned to advance its pivotal Phase III clinical trial, expand development pipeline into additional cancer indications and explore new commercial business development opportunities with its therapeutic technologies

LOS ALTOS, Calif.--(BUSINESS WIRE)-- RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer, Shaun Bagai.

Dear Fellow RenovoRx Shareholders,

The first... More